eligibility_summary
Eligibility: Adults 18–75 with pathologically confirmed non‑keratinizing NPC, recurrent/metastatic after 1st‑line incl. anti‑PD‑1 with oligoprogression (1–5 lesions), suitable for SBRT+tislelizumab+nimotuzumab, PS ≤2, adequate liver/renal/hematologic function, no other cancers or severe organ dysfunction. Exclude: no consent/noncompliance, other trials, uncontrolled infection/major organ failure, PK‑affecting conditions, recent high‑dose steroids, post‑transplant immunosuppression.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study in oligoprogressive recurrent/metastatic nasopharyngeal carcinoma after anti–PD-1 failure tests: 1) SBRT (stereotactic body radiotherapy, hypofractionated high-precision radiation) to induce DNA double-strand breaks and immunogenic tumor cell death, activating cGAS–STING and enhancing antigen presentation, 2) Nimotuzumab (humanized IgG1 anti-EGFR monoclonal antibody) to block EGFR ligand binding/dimerization, inhibiting RAS–MAPK and PI3K–AKT signaling, reducing proliferation and radioresistance, and enabling ADCC, 3) Tislelizumab (humanized IgG4 anti-PD-1 checkpoint inhibitor) to block PD-1/PD-L1/PD-L2 and reinvigorate cytotoxic T cells. Targets: EGFR on tumor cells, PD-1 on T cells, DNA-damage/cGAS–STING, PD-1/PD-L1 axis, EGFR downstream pathways, NK-cell ADCC.